18F-choline Positron-emission-tomography - Computed-tomography Compared to Conventional Imaging for Localizing Diseased Parathyroid Glands in Primary Hyperparathyroidism

Recruiting N/A Interventional Study
Primary Hyperparathyroidism
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Interventional
Purpose
Diagnostic
Participants needed
88 (estimated)
Sponsor
Region Skane · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The goal of this open, single-center, prospective, randomized, clinical study is to compare imaging with \[18F\]fluoromethyl-dimethyl-2-hydroxyethylammonium (18F-choline) positron-emission-tomography - computed-tomography, 18F-ch-PETCT, to conventional imaging with ultrasonography and sestamibi scintigraphy in localizing diseased parathyroid glands in patients diagnosed with primary hyperparathyro…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: Proven primary hyperparathyroidism Indication for surgery Adult (\>18 years) Exclusion Criteria: Inability to give informed consent Allergy to contrast Pregnancy and breastfeeding
Contacts

Martin Almquist

+46-46176245

martin.almquist@med.lu.se

CONTACT